AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesHealth CareGeographicals
Toxoplasmosis, CerebralEncephalitisPyrimethamineSulfadiazineToxoplasmaToxoplasmosis, AnimalAtovaquoneToxoplasmosisAIDS-Related Opportunistic InfectionsAntiprotozoal AgentsNaphthoquinonesEncephalitis, ViralEncephalitis, JapaneseEncephalitis Virus, JapaneseClindamycinSulfadoxineAntimalarialsSulfanilamidesDapsoneAcquired Immunodeficiency SyndromeTetrahydrofolate DehydrogenaseLimbic EncephalitisEncephalitis, ArbovirusEncephalitis Virus, Venezuelan EquineDrug CombinationsEncephalitis, Herpes SimplexDrug ResistanceFolic Acid AntagonistsProguanilBrainEncephalitis, St. LouisEncephalitis VirusesEncephalitis Virus, St. LouisPlasmodium falciparumChloroquineJapanese Encephalitis VaccinesDihydropteroate SynthaseInterferon-gammaEncephalitis Virus, Eastern EquineMalaria, FalciparumTreatment OutcomeEncephalitis Virus, Western EquineParasitic Sensitivity TestsEncephalomyelitis, Venezuelan EquineDrug Therapy, CombinationSulfaleneAnti-N-Methyl-D-Aspartate Receptor EncephalitisEncephalitis Virus, Murray ValleyEncephalomyelitis, EquineEncephalitis, CaliforniaMalariaDNA, ProtozoanTriazinesGangliosidoses, GM2Encephalitis Viruses, JapaneseMefloquineFlavivirusArtemisininsCongoSesquiterpenesSulfamerazineChorioretinitisCameroonCoccidiostatsCombined Modality TherapyFlavivirus Infections
TherapiesTime
Therapies2
  • Current standard therapies for toxoplasmic encephalitis often cause severe adverse events. (cdc.gov)
  • Sincerely, Atrte, Anthony S. Fauci, Director National Institute of Allergy and Infectious Diseases Enclosures NIAID RESPONDS TO ACT UP ALLEGATIONS AND DEMANDS The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases (NIAID) was established to evaluate promising therapies for use against the human immunodeficiency virus (HIV), the cause of AIDS, and the opportunistic infections (OIs) and cancers that characterize AIDS. (nih.gov)
Time1
  • Trimethoprim/sulfamethoxazole (10 mg/kg/d trimethoprim) was first initiated because of limited availability of pyrimethamine plus sulfadiazine at the time, but acute liver toxicity developed on treatment day 6 (increases in levels of aminotransferase/alanine aminotransferase from 24/20 IU/L to 127/145 IU/L[(reference 10-42 IU/L]). Pyrimethamine plus sulfadiazine was started on treatment day 7. (cdc.gov)